Filing Details
- Accession Number:
- 0001567619-21-017166
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-15 18:35:58
- Reporting Period:
- 2021-09-13
- Accepted Time:
- 2021-09-15 18:35:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1528115 | Annexon Inc. | ANNX | Pharmaceutical Preparations (2834) | 275414423 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1818525 | Ted Yednock | C/O Annexon, Inc. 180 Kimball Way, Suite 200 South San Francisco CA 94080 | Evp & Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-09-13 | 15,000 | $1.41 | 15,000 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-09-13 | 1,190 | $5.11 | 16,190 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-09-13 | 16,190 | $20.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-09-13 | 15,000 | $0.00 | 15,000 | $1.41 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-09-13 | 1,190 | $0.00 | 1,190 | $5.11 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
10,615 | 2025-01-22 | No | 4 | M | Direct | |
67,939 | 2029-01-22 | No | 4 | M | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades in prices ranging from $20.00 to $20.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The shares subject to the option vest are fully vested and exercisable.
- 1/48th of the shares subject to the option vest on each monthly anniversary measured from December 12, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.